Forum Diabetologicum - Issue 3/2021
Editorial
165
Immune metabolic view on metabolic syndrome components
Peter Galajda, Marián Mokáň
173
Diabetes mellitus and chronic heart failure
Tomáš Bolek, Matej Samoš, Jakub Benko, Jakub Jurica, Martin Jozef Péč, Marek Cingel, Marián Mokáň
180
Obesity as a risk factor in atrial fibrillation and heart failure
Jakub Jurica, Martin Jozef Péč, Jakub Benko, Tomáš Bolek, Matej Samoš, Peter Galajda, Marián Mokáň
187
Metabolic syndrome in kidney transplant recipients
Karol Graňák, Matej Vnučák, Monika Beliančinová, Margaréta Pytliaková, Ivana Dedinská
193
Metabolic syndrome and intestinal microbiome
Simona Horná, Juraj Krivuš, Renáta Michalová, Peter Galajda, Marián Mokáň
197
Obesity and psoriasis: the context of new knowledge
Martin Jozef Péč, Monika Kučeríková, Jakub Jurica, Jakub Benko, Tomáš Bolek, Juraj Sokol, Tatiana Péčová, Matej Samoš, Peter Galajda, Marián Mokáň
201
207
Benefit of gliflozines on atherosclerosis?
Marián Mokáň, Peter Galajda
213
Oral semaglutide: the future of GLP1 receptor agonism?
Matej Samoš, Marián Mokáň
218
Forum Diabetologicum
2021 Číslo 3
Najčítanejšie v tomto čísle
- Oral semaglutide: the future of GLP1 receptor agonism?
- Metabolic syndrome in kidney transplant recipients
- Obesity as a risk factor in atrial fibrillation and heart failure
- Diabetes mellitus and chronic heart failure